PTCT PTC Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 七月 30, 2026
$63.46
· % 处于52周区间
· 高于低点
· 至高点
$61.2352周低点
$90.8752周高点
市值 (MRQ)
$5.29B
P/E (TTM)
-117.5
EPS (TTM)
$-0.54
收入 (TTM)
$1.01B
PTCT 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$63.46
市值 (MRQ)
$5.29B
P/E (TTM)
-117.5
EPS (TTM)
$-0.54
收入 (TTM)
$1.01B
ROE (TTM)
20.6%
负债/权益 (MRQ)
-3.6
52周区间
$61–$91
PTCT 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
关于 PTC Therapeutics, Inc. - Common Stock 公司概况（来自维基百科）
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.
Products
In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren) marketed for nonsense mutation Duchenne muscular dystrophy. Together, the two products generated revenues of 174 million dollars and 260 million dollars in 2017 and 2018 respectively.
PTC has the commercialization rights for WAYLIVRA (volanesorsen) in Latin America.
In 2018, PTC acquired Agilis Biotherapeutics and a gene therapy candidate, GT-AADC, with its compelling clinical data in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. As of 2024, the AAV based treatment for AADC deficiency has been approved by the FDA and commercialized in the United States as Kebilidi. It is the first FDA-approved gene therapy treatment for AADC deficiency. This same product was granted EMA approval for use in the European Union under the name Upstaza.
Pipeline
In 2020, PTC acquired Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth.
In 2020, PTC announced the FDA approval of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older.
In 2024, Novartis has committed $1 billion upfront in a licensing deal with PTC Therapeutics for an experimental treatment for Huntington’s disease, with the potential for an additional $1.9 billion tied to achieving specific development, regulatory, and commercial milestones. PTC Therapeutics’ therapy, known as PTC518, is an oral medication designed to reduce the production of the mutant protein linked to the genetic mutation responsible for the disease. This mutant protein is believed to contribute to neuronal death, driving disease progression. In June, interim data from a Phase 2 trial indicated that PTC518 successfully lowered levels of the mutant protein in both blood and cerebrospinal fluid.
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
行业板块Healthcare
行业Biotechnology
员工991
国家US
10年表现 收入、净利润、利润率和每股收益趋势
收入$1.73B2016-12-31 → 2025-12-31
EPS$7.782019-12-31 → 2025-12-31
自由现金流$702M2016-12-31 → 2025-12-31
净利率-3.8%2016-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | PTCT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | -117.55年均值 ≈-2.7 | ≈-2.7 | · | · | |
| P/S (TTM) | 5.25年均值 ≈3.8 | ≈3.8 | 55.0 | 低估 | |
| 市净率 (MRQ) | -32.05年均值 ≈481.5 | ≈481.5 | · | · | |
| 企业价值 / EBITDA (TTM) | 20.25年均值 ≈-5.5 | ≈-5.5 | · | · | |
| 股价/自由现金流 (TTM) | -133.25年均值 ≈-10.8 | ≈-10.8 | · | · | |
| 市现率 (TTM) | -173.45年均值 ≈-12.1 | ≈-12.1 | · | · | |
| 市值/营收 (TTM) | 3.65年均值 ≈3.0 | ≈3.0 | · | · | |
| 市值/自由现金流 (TTM) | -91.95年均值 ≈-8.4 | ≈-8.4 | · | · | |
| 市净率（有形资产） (MRQ) | -9.3 | · | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | PTCT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 营业利润率 (TTM) | 12.5%5年均值 ≈-25.9% | ≈-25.9% | -24.1% | 顶尖 | |
| 息税折旧摊销前利润率 (TTM) | 17.9%5年均值 ≈-13.8% | ≈-13.8% | -24.1% | 顶尖 | |
| 税前利润率 (TTM) | -6.6%5年均值 ≈-43.8% | ≈-43.8% | -28.9% | 顶尖 | |
| 净利润率 (TTM) | -3.8%5年均值 ≈-42.4% | ≈-42.4% | -38.1% | 顶尖 | |
| ROA (TTM) | -1.3%5年均值 ≈-12.6% | ≈-12.6% | -27.7% | 顶尖 | |
| ROE (TTM) | 20.6%5年均值 ≈-299.7% | ≈-299.7% | -40.8% | 弱 | |
| ROIC | 1044.7%5年均值 ≈267.1% | ≈267.1% | -37.7% | 顶尖 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | PTCT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 负债/股东权益比率 (MRQ) | -3.65年均值 ≈74.5 | ≈74.5 | · | · | |
| 流动比率 (MRQ) | 3.45年均值 ≈2.1 | ≈2.1 | 8.3 | 低流动性 | |
| 速动比率 (MRQ) | 3.25年均值 ≈2.0 | ≈2.0 | 3.2 | 持平 | |
| 长期负债/股东权益 (MRQ) | -3.25年均值 ≈65.1 | ≈65.1 | · | · |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | PTCT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 114.5%5年均值 ≈41.2% | ≈41.2% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | 35.3%5年均值 ≈28.3% | ≈28.3% | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | 35.4% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | PTCT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 0.85年均值 ≈0.5 | ≈0.5 | 0.4 | 顶尖 | |
| Receivables Turnover (应收账款周转率) | 10.25年均值 ≈6.8 | ≈6.8 | 9.7 | 持平 | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$1.7M | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
105.2%
下次报告
十一月 02, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 5, 2026 | $0.92 | $0.43 | 116.4% |
| 2026年3月31日 | $-0.03 | $-0.48 | 93.7% | |
| 2025年12月31日 | $-1.67 | $0.04 | -4460.3% | |
| 2025年9月30日 | $0.20 | $-1.40 | 114.3% | |
| 2025年6月30日 | $-0.83 | $-1.08 | 23.3% | |
| 2025年3月31日 | $10.04 | $-0.22 | 4743.8% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Cost of Revenue | · | · | · | · | · | · | $12M | $13M | $5M | $0 | $0 | · | |
| R&D Expense | $455M | $534M | $667M | $651M | $541M | $478M | $257M | $172M | $117M | $118M | $122M | $80M | |
| SG&A Expense | $347M | $301M | $333M | $326M | $286M | $245M | $203M | $154M | $121M | $97M | $82M | $45M | |
| Operating Expenses | $864M | $1.11B | $1.38B | $1.15B | $913M | $813M | $548M | $380M | $259M | $215M | $204M | $125M | |
| Operating Income | $867M | $-303M | $-440M | $-447M | $-374M | $-432M | $-241M | $-116M | $-64M | $-132M | $-167M | $-99M | |
| Other Non-op | $-18M | $7M | $10M | $-49M | $-58M | $85M | $14M | $129.0K | $-1M | $-1M | $-465.0K | $-213.0K | |
| Pretax Income | $697M | $-363M | $-696M | $-587M | $-518M | $-403M | $-240M | $-128M | $-78M | $-142M | $-170M | $-98M | |
| Income Tax | $14M | $176.0K | $-70M | $-28M | $6M | $35M | $12M | $-29.0K | $1M | $569.0K | $485.0K | $-5M | |
| Net Income | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| EPS (Basic) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | · | · | $-2.97 | |
| EPS (Diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | · | · | · | · | $-2.97 | |
| Shares (Basic) | 79,534,290 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| Shares (Diluted) | 88,311,494 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| EBITDA | $906M | $-227M | $-203M | · | $-310M | $-388M | $-209M | $-90M | $-47M | $-132M | $-167M | $-99M |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $985M | $780M | $594M | $280M | $190M | $209M | $288M | $169M | $112M | $58M | $58M | $50M | |
| Short-term Investments | $961M | $360M | $283M | $131M | $584M | $895M | $399M | $58M | $79M | $173M | $281M | $265M | |
| Receivables | $182M | $159M | $161M | $156M | $110M | $70M | $56M | $68M | $40M | $25M | $11M | $4M | |
| Inventory | $80M | $23M | $31M | $22M | $16M | $19M | $19M | $16M | $11M | $0 | · | · | |
| Prepaid Expense | $67M | $44M | $150M | $106M | $55M | $39M | $18M | $9M | $7M | $5M | $6M | $4M | |
| Current Assets | $2.27B | $1.37B | $1.22B | $694M | $954M | $1.23B | $779M | $321M | $249M | $261M | $356M | $324M | |
| PP&E (Net) | $55M | $61M | $87M | $73M | $53M | $34M | $22M | $13M | $8M | $7M | $9M | $9M | |
| PP&E (Gross) | $102M | $94M | $138M | $110M | $80M | $52M | $33M | $20M | $41M | $38M | $37M | $34M | |
| Accum. Depreciation | $47M | $33M | $51M | $37M | $27M | $18M | $12M | $7M | $33M | $31M | $28M | $25M | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $0 | · | · | · | |
| Intangibles | $389M | $119M | $379M | $706M | $725M | $715M | $710M | $701M | $133M | $0 | · | · | |
| Total Assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Accounts Payable | $45M | $17M | $6M | $27M | $23M | $19M | $10M | $6M | $15M | $6M | $6M | $4M | |
| Current Liabilities | $968M | $581M | $603M | $406M | $509M | $277M | $236M | $167M | $82M | $50M | $45M | $32M | |
| Capital Leases | $94M | $75M | $98M | $101M | $74M | $79M | $9M | · | · | · | · | · | |
| Deferred Tax | · | · | $56M | $103M | $137M | $137M | $131M | $122M | $0 | · | · | · | |
| Other Non-current Liabilities | $14M | $21M | $141.0K | $3M | · | $1M | $141.0K | $58.0K | $243.0K | $335.0K | $2M | $2M | |
| Total Liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768M | $235M | $150M | $139M | $35M | |
| Long-term Debt | · | · | · | · | $431M | · | $314M | $153M | $145M | · | · | · | |
| Total Debt | $287M | $285M | $284M | · | $431M | $309M | $314M | $153M | $145M | $98M | $95M | · | |
| Common Stock | $80.0K | $77.0K | $75.0K | $72.0K | $71.0K | $70.0K | $62.0K | $51.0K | $42.0K | $34.0K | $34.0K | $33.0K | |
| Paid-in Capital | $2.75B | $2.57B | $2.47B | $2.31B | $2.12B | $2.17B | $1.80B | $1.29B | $967M | $856M | $820M | $722M | |
| Retained Earnings | $-2.96B | $-3.65B | $-3.28B | $-2.66B | $-2.10B | $-1.63B | $-1.19B | $-939M | $-814M | $-735M | $-593M | $-423M | |
| AOCI | $11M | $-26M | $-1M | $5M | $-24M | $-61M | $-11M | $1M | $4M | $-1M | $-1M | $-737.0K | |
| Stockholders' Equity | $-205M | $-1.10B | $-819M | $-347M | $1M | $482M | $594M | $351M | $156M | $120M | $226M | $298M | |
| Liabilities + Equity | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Shares Outstanding | 81,474,366 | 77,704,188 | 75,708,889 | 73,104,692 | 70,828,226 | 69,718,096 | 61,935,870 | 50,606,147 | 41,612,395 | 34,169,410 | 33,916,559 | 32,898,392 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $39M | $76M | $237M | $129M | $64M | $43M | $32M | $26M | $18M | $3M | $3M | · | |
| Stock-based Comp | $75M | $75M | $102M | $110M | $104M | $70M | $42M | $33M | $31M | $35M | $34M | $19M | |
| Deferred Tax | $-3.0K | $-56M | $-47M | $-34M | $377.0K | $6M | $9M | $0 | $199.0K | $-199.0K | $0 | $0 | |
| Amort. of Intangibles | $25M | $61M | $223M | $117M | $55M | $37M | $28M | $23M | $15M | $0 | $0 | · | |
| Restructuring | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Other Non-cash | $-85M | $161M | $177M | · | $105M | $124M | $70M | $41M | $20M | · | · | · | |
| Operating Cash Flow | $711M | $-108M | $-158M | $-357M | $-251M | $-194M | $-99M | $-28M | $-10M | $-104M | $-124M | $-57M | |
| CapEx | $9M | $7M | $28M | $32M | $28M | $18M | $14M | $7M | $3M | $2M | $3M | $5M | |
| Investing Cash Flow | $-862M | $44M | $-177M | $290M | $219M | $-562M | $-387M | $-43M | $13M | $104M | $-21M | $-145M | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | $-49.0K | |
| Stock Issued | · | · | · | · | · | $28M | $324M | $118M | $0 | $0 | $0 | $236M | |
| Net Stock Activity | · | · | · | · | · | $28M | $324M | $118M | · | $0 | · | $236M | |
| Financing Cash Flow | $331M | $256M | $646M | $168M | $21M | $669M | $613M | $132M | $44M | $968.0K | $154M | $237M | |
| Net Change in Cash | $203M | $185M | $314M | $99M | $-19M | $-79M | $126M | $58M | $53M | $299.0K | $8M | $34M | |
| Taxes Paid | $37M | $18M | $14M | $5M | $8M | $26M | $2M | $2M | $1M | $943.0K | $111.0K | $0 | |
| Free Cash Flow | $702M | $-114M | $-187M | · | $-280M | $-212M | $-112M | $-35M | $-13M | $-105M | $-127M | $-62M |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 50.1% | -37.5% | -46.9% | · | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% | -454.6% | -393.8% | |
| Net Margin | 39.4% | -45.0% | -66.8% | · | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% | -463.6% | -371.4% | |
| Pretax Margin | 40.2% | -45.0% | -74.2% | · | -96.2% | -105.8% | -78.2% | -48.4% | -40.0% | -171.1% | -462.3% | -390.0% | |
| EBITDA Margin | 52.3% | -28.1% | -21.6% | · | -57.6% | -102.0% | -68.1% | -33.8% | -24.0% | -159.7% | -454.6% | -393.8% | |
| ROA | 29.7% | -20.2% | -34.8% | · | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.8% | -48.6% | -38.6% | |
| ROE | -331.5% | 33.8% | 84.1% | · | -985.1% | -88.3% | -40.0% | -34.8% | -57.2% | -82.2% | -65.0% | -43.1% | |
| ROIC | 1044.7% | 37.2% | 74.0% | · | -87.4% | -59.4% | -27.8% | -23.0% | -21.7% | -60.9% | -52.3% | -31.7% |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 2.4 | 2.0 | · | 1.9 | 4.4 | 3.3 | 1.9 | 3.0 | 5.3 | 7.8 | 10.0 | |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 | 4.2 | 3.1 | 1.8 | 2.8 | 5.2 | 7.7 | 9.8 | |
| Debt / Equity | -1.4 | -0.3 | -0.3 | · | 300.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · | |
| LT Debt / Equity | · | -0.3 | -0.3 | · | 196.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.4 | 0.5 | · | 0.3 | 0.2 | 0.2 | 0.4 | 0.6 | 0.3 | 0.1 | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | 0.7 | · | 0.9 | · | · | · | |
| Receivables Turnover | 10.2 | 5.1 | 5.9 | · | 6.0 | 6.1 | 5.0 | 4.9 | 6.0 | 4.6 | 4.7 | 9.3 |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-2.52 | $-14.13 | $-10.81 | · | $0.02 | $6.91 | $9.60 | $6.93 | $3.76 | $3.50 | $6.66 | $9.07 | |
| Revenue / Share | $19.60 | $10.50 | $12.53 | · | $7.64 | · | · | · | · | · | · | $0.80 | |
| Cash Flow / Share | $8.05 | $-1.40 | $-2.12 | · | $-3.57 | · | · | · | · | · | · | $-1.81 | |
| Cash / Share | $12.09 | $10.03 | $7.85 | · | $2.68 | $3.00 | $4.65 | $3.35 | $2.69 | $1.71 | $1.71 | $1.51 | |
| EPS (TTM) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-3.21 | $-3.21 | $-3.21 | $-3.21 | $-2.97 |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 114.5% | -14.0% | 34.2% | 29.8% | 41.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 35.3% | 14.4% | 35.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 35.4% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Net Income TTM | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| Market Cap | $6.19B | $3.51B | $2.09B | · | $2.82B | $4.25B | $2.97B | $1.74B | $694M | $373M | $1.10B | $1.70B | |
| Enterprise Value | $4.53B | $2.65B | $1.49B | · | $2.48B | $3.46B | $2.60B | $1.66B | $648M | $239M | $855M | · | |
| P/E | 9.8 | -9.5 | -3.3 | -4.9 | -5.4 | -9.2 | -11.2 | -10.7 | -5.2 | -3.4 | -10.1 | -17.4 | |
| P/S | 3.6 | 4.3 | 2.2 | · | 5.2 | 11.2 | 9.7 | 6.6 | 3.6 | 4.5 | 29.9 | 67.5 | |
| P/B | -30.1 | -3.2 | -2.5 | · | 1961.8 | 8.8 | 5.0 | 5.0 | 4.4 | 3.1 | 4.9 | 5.7 | |
| P / Cash Flow | 8.7 | -32.6 | -13.2 | · | -11.2 | -21.9 | -30.2 | -62.8 | -69.0 | -3.6 | -8.8 | -29.7 | |
| P / FCF | 8.8 | -30.7 | -11.2 | · | -10.1 | -20.1 | -26.5 | -50.0 | -52.7 | -3.5 | -8.6 | -27.5 | |
| EV / EBITDA | 5.0 | -11.7 | -7.4 | · | -8.0 | -8.9 | -12.5 | -18.6 | -13.9 | -1.8 | -5.1 | · | |
| EV / FCF | 6.5 | -23.2 | -8.0 | · | -8.9 | -16.3 | -23.2 | -47.9 | -49.2 | -2.3 | -6.7 | · | |
| EV / Revenue | 2.6 | 3.3 | 1.6 | · | 4.6 | 9.1 | 8.5 | 6.3 | 3.3 | 2.9 | 23.2 | · | |
| Earnings Yield | 10.2% | -10.5% | -30.4% | -20.4% | -18.6% | -10.9% | -8.9% | -9.3% | -19.2% | -29.4% | -9.9% | -5.7% |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $361M | $273M | $165M | $211M | $179M | $1.18B | $213M | $197M | $187M | $210M | $307M | $197M | $214M | $220M | $167M | $217M | |
| R&D Expense | $99M | $101M | $133M | $100M | $113M | $109M | $125M | $161M | $132M | $116M | $121M | $164M | $186M | $195M | $189M | $165M | |
| SG&A Expense | $81M | $86M | $97M | $84M | $85M | $81M | $85M | $73M | $70M | $73M | $76M | $81M | $88M | $87M | $93M | $80M | |
| Operating Expenses | $212M | $228M | $236M | $208M | $214M | $206M | $376M | $251M | $227M | $256M | $301M | $315M | $423M | $338M | $368M | $285M | |
| Operating Income | $149M | $45M | $-71M | $3M | $-35M | $970M | $-162M | $-55M | $-40M | $-45M | $6M | $-118M | $-210M | $-118M | $-200M | $-68M | |
| Other Non-op | $-3M | $2M | $-13M | $7M | $-6M | $-6M | $9M | $-2M | $-2M | $2M | $19M | $-20M | $1M | $10M | $35M | $-38M | |
| Pretax Income | $98M | $-2M | $-139M | $-23M | $-71M | $930M | $-95M | $-98M | $-86M | $-85M | $-157M | $-167M | $-237M | $-135M | $-190M | $-127M | |
| Income Tax | $14M | $347.0K | $-4M | $-39M | $-6M | $63M | $-29M | $9M | $13M | $7M | $-1M | $-34M | $-39M | $4M | $-19M | $-18M | |
| Net Income | $83M | $-3M | $-135M | $16M | $-65M | $867M | $-66M | $-107M | $-99M | $-92M | $-156M | $-133M | $-199M | $-139M | $-171M | $-109M | |
| EPS (Basic) | $1.01 | $-0.03 | $-1.88 | $0.20 | $-0.83 | $11.09 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| EPS (Diluted) | $0.92 | $-0.03 | $-1.63 | $0.20 | $-0.83 | $10.04 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| Shares (Basic) | 83,006,808 | 82,521,023 | · | 78,471,119 | 78,151,240 | 78,115,836 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| Shares (Diluted) | 92,020,009 | 82,521,023 | · | 87,115,369 | 78,151,240 | 86,385,922 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| EBITDA | $149M | $60M | · | $3M | $-35M | $977M | · | $-55M | $-40M | $10M | · | $-118M | $-210M | $-75M | · | $-68M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.05B | $834M | $985M | $673M | $1.02B | $1.48B | $780M | $526M | $655M | $548M | · | $165M | $208M | $167M | · | $104M | |
| Short-term Investments | $1.18B | $1.06B | $961M | $1.02B | $972M | $547M | $360M | $487M | $439M | $336M | · | $130M | $130M | $119M | · | $184M | |
| Receivables | $239M | $220M | $182M | $203M | $196M | $210M | $159M | $200M | $187M | $198M | · | $166M | $178M | $202M | · | $124M | |
| Inventory | $91M | $76M | $80M | $53M | $34M | $22M | $23M | $36M | $32M | $30M | · | $36M | $32M | $27M | · | $15M | |
| Prepaid Expense | $58M | $66M | $67M | $64M | $54M | $57M | $44M | $33M | $46M | $56M | · | $44M | $42M | $99M | · | $90M | |
| Current Assets | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | $2.32B | $1.37B | $1.28B | $1.36B | $1.17B | · | $540M | $590M | $613M | · | $517M | |
| PP&E (Net) | $51M | $53M | $55M | $57M | $57M | $59M | $61M | $63M | $66M | $93M | · | $85M | $82M | $79M | · | $67M | |
| PP&E (Gross) | · | · | $102M | · | · | · | $94M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $33M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | · | $82M | $82M | $82M | · | $82M | |
| Intangibles | $403M | $381M | $389M | $396M | $144M | $118M | $119M | $330M | $330M | $330M | · | $423M | $452M | $686M | · | $750M | |
| Total Assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Accounts Payable | $40M | $25M | $45M | $37M | $27M | $15M | $17M | $13M | $24M | $27M | · | $19M | $26M | $26M | · | $21M | |
| Current Liabilities | $771M | $924M | $968M | $866M | $628M | $595M | $581M | $611M | $610M | $575M | · | $492M | $476M | $442M | · | $420M | |
| Capital Leases | $88M | $90M | $94M | $95M | $71M | $74M | $75M | $83M | $79M | $105M | · | $100M | $100M | $100M | · | $102M | |
| Deferred Tax | · | · | · | · | · | · | · | $56M | $56M | $56M | · | $52M | $52M | $103M | · | $137M | |
| Other Non-current Liabilities | $15M | $14M | $14M | $3M | $8M | $22M | $21M | $77.0K | $141.0K | $141.0K | · | $141.0K | $141.0K | $141.0K | · | $5M | |
| Total Liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B | $2.80B | $2.90B | $2.90B | $2.68B | · | $1.93B | $1.92B | $2.07B | · | $1.80B | |
| Long-term Debt | $591M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $591M | $287M | · | $286M | $286M | $286M | · | $285M | $285M | $285M | · | $573M | $573M | $572M | · | $283M | |
| Common Stock | $82.0K | $81.0K | $80.0K | $79.0K | $78.0K | $78.0K | $77.0K | $76.0K | $76.0K | $76.0K | · | $75.0K | $75.0K | $73.0K | · | $71.0K | |
| Paid-in Capital | $2.71B | $2.78B | $2.75B | $2.67B | $2.63B | $2.61B | $2.57B | $2.53B | $2.51B | $2.49B | · | $2.45B | $2.42B | $2.34B | · | $2.22B | |
| Retained Earnings | $-2.88B | $-2.97B | $-2.96B | $-2.83B | $-2.85B | $-2.78B | $-3.65B | $-3.58B | $-3.47B | $-3.38B | · | $-3.13B | $-2.99B | $-2.80B | · | $-2.49B | |
| AOCI | $6M | $8M | $11M | $6M | $7M | $-14M | $-26M | $-4M | $-16M | $-6M | · | $10M | $-1M | $-2M | · | $36M | |
| Stockholders' Equity | $-165M | $-180M | $-205M | $-156M | $-207M | $-186M | $-1.10B | $-1.05B | $-980M | $-894M | $-819M | $-671M | $-579M | $-458M | $-347M | $-227M | |
| Liabilities + Equity | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Shares Outstanding | 83,327,286 | 82,882,024 | 81,474,366 | 79,931,766 | 79,378,145 | 79,225,276 | 77,704,188 | 76,952,124 | 76,900,123 | 76,653,960 | · | 75,459,022 | 75,318,233 | 74,012,034 | · | 71,854,892 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $16M | $15M | $13M | $11M | $8M | $7M | $7M | $6M | $7M | $55M | $81M | $62M | $51M | $43M | $39M | $34M | |
| Stock-based Comp | $23M | $23M | $19M | $19M | $19M | $18M | $17M | $20M | $19M | $18M | $17M | $27M | $29M | $29M | $27M | $29M | |
| Deferred Tax | · | $-10.0K | $1.0K | · | · | $2.0K | $-56M | $-3.0K | $2.0K | $-1.0K | $4M | $-2.0K | $-51M | $-4.0K | · | · | |
| Amort. of Intangibles | $12M | $12M | $9M | $8M | $4M | $4M | $3M | $3M | $3M | $52M | $77M | $59M | $47M | $39M | $36M | $31M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $23M | $8M | · | · | · | |
| Other Non-cash | · | $-95M | · | · | · | $-22M | · | · | · | $89M | · | · | · | $38M | · | · | |
| Operating Cash Flow | $129M | $-59M | $-34M | $-66M | $-58M | $870M | $-30M | $-77M | $-71M | $71M | $-100M | $-15M | $-14M | $-29M | $-166M | $-38M | |
| CapEx | $2M | $1M | $2M | $3M | $1M | $2M | $4M | $522.0K | $-7M | $10M | $6M | $6M | $6M | $10M | $9M | $5M | |
| Investing Cash Flow | $-123M | $-94M | $34M | $-290M | $-422M | $-184M | $268M | $-43M | $-66M | $-115M | $-94M | $-30M | $-24M | $-29M | $32M | $136M | |
| Financing Cash Flow | $212M | $6M | $303M | $15M | $4M | $9M | $26M | $-18M | $246M | $540.0K | $620M | $3M | $18M | $4M | $303M | $-140M | |
| Net Change in Cash | $216M | $-148M | $312M | $-347M | $-463M | $701M | $256M | $-129M | $104M | $-46M | $429M | $-43M | $-9M | $-62M | $175M | $-54M | |
| Taxes Paid | · | · | $-3M | $936.0K | $36M | $3M | $5M | $7M | $4M | $2M | $524.0K | $4M | $7M | $2M | $893.0K | $1M | |
| Free Cash Flow | · | $-60M | · | · | · | $868M | · | · | · | $61M | · | · | · | $-40M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.3% | 16.5% | · | 1.4% | -19.5% | 82.5% | · | -27.7% | -21.5% | -21.6% | · | -60.1% | -98.0% | -53.4% | · | -31.4% | |
| Net Margin | 23.2% | -1.0% | · | 7.5% | -36.2% | 73.7% | · | -54.2% | -53.1% | -43.6% | · | -67.6% | -93.0% | -63.0% | · | -50.3% | |
| Pretax Margin | 27.1% | -0.90% | · | -10.9% | -39.7% | 79.1% | · | -49.8% | -45.9% | -40.3% | · | -84.8% | -111.1% | -61.3% | · | -58.6% | |
| EBITDA Margin | 41.3% | 22.1% | · | 1.4% | -19.5% | 83.1% | · | -27.7% | -21.5% | 4.7% | · | -60.1% | -98.0% | -33.9% | · | -31.4% | |
| ROA | 2.8% | -0.10% | · | 0.71% | -2.9% | 39.0% | · | -6.9% | -6.1% | -5.4% | · | -9.4% | -12.7% | -8.2% | · | -6.1% | |
| ROE | -44.9% | 1.5% | · | -2.6% | 10.9% | -160.5% | · | 12.4% | 12.7% | 13.6% | · | 29.6% | 52.2% | 50.7% | · | 179.2% | |
| ROIC | 30.0% | 48.2% | · | -1.6% | -40.2% | 904.6% | · | 7.7% | 6.7% | 8.1% | · | 96.6% | 2648.9% | -105.7% | · | -104.9% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 2.4 | · | 2.3 | 3.6 | 3.9 | · | 2.1 | 2.2 | 2.0 | · | 1.1 | 1.2 | 1.4 | · | 1.2 | |
| Quick Ratio | 3.2 | 2.3 | · | 2.2 | 3.5 | 3.8 | · | 2.0 | 2.1 | 1.9 | · | 0.9 | 1.1 | 1.1 | · | 1.0 | |
| Debt / Equity | -3.6 | -1.6 | · | -1.8 | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 | |
| LT Debt / Equity | -3.2 | · | · | · | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.5 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.7 | 1.3 | · | 1.0 | 0.9 | 5.8 | · | 1.1 | 1.0 | 1.1 | · | 1.4 | 1.4 | 1.3 | · | 2.0 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.98 | $-2.18 | · | $-1.95 | $-2.60 | $-2.34 | · | $-13.70 | $-12.75 | $-11.66 | · | $-8.89 | $-7.69 | $-6.18 | · | $-3.16 | |
| Revenue / Share | $3.92 | $3.30 | · | $2.42 | $2.29 | $13.61 | · | $2.56 | $2.43 | $2.75 | · | $2.61 | $2.86 | $2.99 | · | $3.03 | |
| Cash Flow / Share | · | $-0.72 | · | · | · | $10.07 | · | · | · | $0.93 | · | · | · | $-0.40 | · | · | |
| Cash / Share | $12.60 | $10.06 | · | $8.41 | $12.82 | $18.68 | · | $6.84 | $8.51 | $7.15 | · | $2.19 | $2.77 | $2.26 | · | $1.45 | |
| EPS (TTM) | $-0.54 | $-2.29 | · | $8.56 | $6.97 | $6.51 | · | $-5.95 | $-6.32 | $-7.69 | · | $-8.65 | $-8.42 | $-7.89 | · | $-7.47 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.01B | $827M | · | $1.78B | $1.76B | $1.77B | · | $901M | $900M | $928M | · | $798M | $819M | $770M | · | $697M | |
| Net Income TTM | $-38M | $-187M | · | $752M | $629M | $595M | · | $-453M | $-480M | $-579M | · | $-642M | $-618M | $-571M | · | $-531M | |
| Market Cap | $6.80B | $5.65B | · | $4.91B | $3.88B | $4.04B | · | $2.85B | $2.35B | $2.23B | · | $1.69B | $3.06B | $3.59B | · | $3.61B | |
| Enterprise Value | $5.16B | $4.04B | · | $3.50B | $2.17B | $2.30B | · | $2.13B | $1.54B | $1.63B | · | $1.97B | $3.30B | $3.87B | · | $3.60B | |
| P/E | -151.1 | -29.8 | · | 7.2 | 7.0 | 7.8 | · | -6.2 | -4.8 | -3.8 | · | -2.6 | -4.8 | -6.1 | · | -6.7 | |
| P/S | 6.7 | 6.8 | · | 2.8 | 2.2 | 2.3 | · | 3.2 | 2.6 | 2.4 | · | 2.1 | 3.7 | 4.7 | · | 5.2 | |
| P/B | -41.1 | -31.3 | · | -31.5 | -18.8 | -21.7 | · | -2.7 | -2.4 | -2.5 | · | -2.5 | -5.3 | -7.8 | · | -15.9 | |
| P / Cash Flow | · | -95.6 | · | · | · | 4.6 | · | · | · | 31.5 | · | · | · | -121.6 | · | · | |
| EV / Revenue | 5.1 | 4.9 | · | 2.0 | 1.2 | 1.3 | · | 2.4 | 1.7 | 1.8 | · | 2.5 | 4.0 | 5.0 | · | 5.2 | |
| Earnings Yield | -0.66% | -3.4% | · | 14.0% | 14.3% | 12.8% | · | -16.0% | -20.7% | -26.4% | · | -38.6% | -20.7% | -16.3% | · | -14.9% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $1.73B | $807M | $938M | $699M | $539M |
| 营业利润率 % | 50.1% | -37.5% | -46.9% | · | -69.5% |
| 净收入 | $683M | $-363M | $-627M | $-559M | $-524M |
| 稀释后每股收益 (EPS) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | -1.4 | -0.3 | -0.3 | · | 300.0 |
| 流动比率 | 2.3 | 2.4 | 2.0 | · | 1.9 |
| 速动比率 | 2.2 | 2.2 | 1.7 | · | 1.7 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $702M | $-114M | $-187M | · | $-280M |
机构持有人 (13F) 403 家申报者 · $8.6B 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
403
持有价值
$8.6B
新仓位
76
已退出持仓
43
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 76 (+7 与上一季度对比) | 43 (-7 与上一季度对比) | 140 (+3 与上一季度对比) | 114 (+10 与上一季度对比) | -1.4M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| BlackRock, Inc. | $1139088671 | 13964554 | 13.21% | 股份 |
| VANGUARD GROUP INC | $668691300 | 8803203 | 7.75% | 股份 |
| RTW INVESTMENTS, LP | $631875072 | 7746415 | 7.33% | 股份 |
| JANUS HENDERSON GROUP PLC | $489997100 | 7193433 | 5.68% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $401986014 | 4928111 | 4.66% | 股份 |
| STATE STREET CORP | $375136515 | 4598952 | 4.35% | 股份 |
| WELLINGTON MANAGEMENT GROUP LLP | $336743228 | 4128273 | 3.90% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $305000589 | 3739127 | 3.54% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $180089116 | 2207376 | 2.09% | 股份 |
| TORONTO DOMINION BANK | $176668031 | 2165846 | 2.05% | 股份 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $159563645 | 1956156 | 1.85% | 股份 |
| Hood River Capital Management LLC | $141818662 | 1738613 | 1.64% | 股份 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $140519660 | 1722688 | 1.63% | 股份 |
| D. E. Shaw & Co., Inc. | $126345323 | 1548919 | 1.47% | 股份 |
| TANG CAPITAL MANAGEMENT LLC | $122355000 | 1500000 | 1.42% | 股份 |
| BANK OF AMERICA CORP /DE/ | $118462234 | 1452277 | 1.37% | 股份 |
| Driehaus Capital Management LLC | $117469528 | 1440107 | 1.36% | 股份 |
| FMR LLC | $114056206 | 1398261 | 1.32% | 股份 |
| Jefferies Financial Group Inc. | $110693916 | 1357042 | 1.28% | 股份 |
| FULLER & THALER ASSET MANAGEMENT, INC. | $94361749 | 1156819 | 1.09% | 股份 |
| Pictet Asset Management Holding SA | $93629635 | 1147844 | 1.09% | 股份 |
| MORGAN STANLEY | $90026886 | 1103675 | 1.04% | 股份 |
| ARMISTICE CAPITAL, LLC | $87393690 | 1071395 | 1.01% | 股份 |
| Blue Sparrow, LLC /DE | $85705599 | 1050700 | 0.99% | 股份 |
| FRANKLIN RESOURCES INC | $83799082 | 1027327 | 0.97% | 股份 |
| Invesco Ltd. | $76804761 | 941581 | 0.89% | 股份 |
| Palo Alto Investors LP | $74950268 | 918846 | 0.87% | 股份 |
| NORTHERN TRUST CORP | $71783966 | 880029 | 0.83% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64449436 | 790112 | 0.75% | 股份 |
| CITADEL ADVISORS LLC | $60999840 | 747822 | 0.71% | 股份 |
| RENAISSANCE TECHNOLOGIES LLC | $59015895 | 723500 | 0.68% | 股份 |
| Boston Partners | $58606553 | 718574 | 0.68% | 股份 |
| JUPITER ASSET MANAGEMENT LTD | $57706697 | 707450 | 0.67% | 股份 |
| MARSHALL WACE, LLP | $57489476 | 704787 | 0.67% | 股份 |
| JPMORGAN CHASE & CO | $56073502 | 684042 | 0.65% | 股份 |
| ARMISTICE CAPITAL, LLC | $53836200 | 660000 | 0.62% | 买入期权 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $53377940 | 654382 | 0.62% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $52017434 | 637704 | 0.60% | 股份 |
| GOLDMAN SACHS GROUP INC | $50430408 | 618247 | 0.58% | 股份 |
| LOOMIS SAYLES & CO L P | $48156807 | 590374 | 0.56% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $47953943 | 587887 | 0.56% | 股份 |
| Nuveen, LLC | $47622931 | 583829 | 0.55% | 股份 |
| Bank of New York Mellon Corp | $45145865 | 553462 | 0.52% | 股份 |
| PRINCIPAL FINANCIAL GROUP INC | $44181166 | 541635 | 0.51% | 股份 |
| VOYA INVESTMENT MANAGEMENT LLC | $43992251 | 539319 | 0.51% | 股份 |
| Ensign Peak Advisors, Inc | $41442128 | 508056 | 0.48% | 股份 |
| AMERICAN CENTURY COMPANIES INC | $40866277 | 500995 | 0.47% | 股份 |
| FEDERATED HERMES, INC. | $39432896 | 483424 | 0.46% | 股份 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $36050432 | 441957 | 0.42% | 股份 |
| Parkman Healthcare Partners LLC | $35539315 | 435691 | 0.41% | 股份 |
激进投资者及 5%+ 股东 3 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Brookside Capital Partners Fund, L.P., Brookside Capital Trading Fund, L.P. ×5 申报 | 2015年1月30日 | · | 初始申报 | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. (“HBM”) ×2 申报 | 2014年11月12日 | · | 初始申报 | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. | 2013年7月5日 | · | 初始申报 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 37 位内幕人士 · 15 位高管 · 20 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER | 2026年8月4日 S | 383868 | 0 | 13 | $-4219888 |
| Stuart Walter Peltz | CHIEF EXECUTIVE OFFICER | 2023年1月31日 S | 54903 | 0 | 0 | $0 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 2026年7月14日 S | 83986 | 0 | 3 | $-652864 |
| Emily Luisa Hill | CHIEF FINANCIAL OFFICER | 2023年3月27日 S | 38925 | 0 | 0 | $0 |
| Shane William Charles Kovacs | Chief Financial Officer | 2017年5月9日 M | 37850 | 0 | 0 | $0 |
| Claudia De Oliveira Ribeiro Hirawat | President | 2015年1月15日 M | 39247 | 0 | 0 | $0 |
| Marcio Souza | Chief Operating Officer | 2020年2月10日 M | 6744 | 0 | 0 | $0 |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026年8月17日 M | 105272 | 0 | 63 | $-5955553 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 2026年7月9日 M | 60299 | 0 | 62 | $-25989291 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 2026年6月17日 M | 70199 | 0 | 5 | $-1941426 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 2026年6月10日 S | 73411 | 0 | 28 | $-7477160 |
| Lee Scott Golden | EVP & CHIEF MEDICAL OFFICER | 2026年4月2日 S | 79115 | 0 | 6 | $-1081515 |
| Mark Rothera | Chief Commercial Officer | 2017年5月24日 M | 33739 | 0 | 0 | $0 |
| Tuyen Ong | Chief Medical Officer | 2017年1月3日 A | 6000 | 0 | 0 | $0 |
| Robert J. Spiegel | Chief Medical Officer | 2016年1月4日 A | 3239 | 0 | 0 | $0 |
| Glenn Steele JR MD PHD | 董事 | 2026年9月30日 M | 22500 | 0 | 2 | $-1698120 |
| Michael Schmertzler | 董事 | 2026年9月17日 S | 1296594 | 0 | 16 | $-6313453 |
| Hege Elisabeth Sollie-Zetlmayer | 董事 | 2026年7月28日 A | 52526 | 0 | 0 | $0 |
| Mary L. Smith | 董事 | 2026年7月9日 M | 21813 | 0 | 2 | $-1425060 |
| Jessica Caroline Chutter | 董事 | 2026年3月24日 A | 7333 | 0 | 0 | $0 |
| Stephanie Okey | 董事 | 2026年3月10日 M | 8000 | 0 | 3 | $-1463076 |
| Emma Reeve | 董事 | 2026年1月5日 M | 10666 | 0 | 15 | $-4229530 |
| Alethia Young | 董事 | 2026年1月2日 A | 21067 | 0 | 0 | $0 |
| Allan Steven Jacobson | 董事 | 2026年1月2日 A | 21451 | 0 | 11 | $-2912018 |
| Jerome B Zeldis | 董事 | 2026年1月2日 A | 22500 | 0 | 0 | $0 |
| William F. Bell Jr. | 董事 | 2024年2月15日 A | 10333 | 0 | 0 | $0 |
| Dawn Svoronos | 董事 | 2022年6月9日 S | 29017 | 0 | 0 | $0 |
| Cameron Geoffrey Mcdonough | 董事 | 2017年1月3日 A | · | 0 | 0 | $0 |
| Adam Koppel | 董事 | 2017年1月3日 A | 2333333 | 0 | 0 | $0 |
| Ronald C Renaud JR | 董事 | 2017年1月3日 A | · | 0 | 0 | $0 |
| Richard Aldrich | 董事 | 2015年6月8日 M | 0 | 0 | 0 | $0 |
| Michael L Kranda | 董事 | 2015年3月16日 S | 2242 | 0 | 0 | $0 |
| Axel Bolte | 董事 | 2013年6月25日 P | 20000 | 0 | 0 | $0 |
| HBM Healthcare Investments (Cayman) Ltd. | 10% 所有者 | 2013年12月17日 S | 2441504 | 0 | 0 | $0 |
| David P Southwell | · | 2026年1月2日 A | 20850 | 0 | 0 | $0 |
| Complete Pharma Holdings II, LLC | · | 2017年4月28日 J | 0 | 0 | 0 | $0 |
| CREDIT SUISSE/ | · | 2013年6月25日 C | 2256882 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 68 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| IBRN · iShares Trust | 3.74% | 4145 SH | 2026年9月11日 | 每日 |
| PSCH · Invesco Exchange-Traded Fund Trus... | 2.91% | 80293 SH | 2026年10月1日 | 每日 |
| PBE · Invesco Exchange-Traded Fund Trust | 2.44% | 159717 SH | 2026年10月1日 | 每日 |
| MEDI · Harbor ETF Trust | 1.31% | 7913 NS | 2026年7月31日 | N-PORT |
| BBP · ETFis Series Trust I | 1.25% | 18062 NS | 2026年7月31日 | N-PORT |
| RZG · Invesco Exchange-Traded Fund Trust | 1.24% | 22852 SH | 2026年10月1日 | 每日 |
| JSML · Janus Detroit Street Trust | 1.03% | 54825 NS | 2026年7月31日 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0.94% | 145033 NS | 2026年7月31日 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0.74% | 98733 SH | 2026年8月19日 | 每日 |
| VAMO · Cambria ETF Trust | 0.72% | 11494 NS | 2026年7月31日 | N-PORT |
| VMAX · Lattice Strategies Trust | 0.71% | 5120 NS | 2026年7月31日 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.63% | 46006 NS | 2026年7月31日 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund ... | 0.49% | 658 NS | 2026年7月31日 | N-PORT |
| HQGO · Lattice Strategies Trust | 0.42% | 3031 NS | 2026年7月31日 | N-PORT |
| IBB · iShares Trust | 0.40% | 613266 SH | 2026年9月11日 | 每日 |
| BRNY · EA Series Trust | 0.39% | 33006 NS | 2026年7月31日 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0.37% | 290018 SH | 2026年8月19日 | 每日 |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 0.35% | 5891 SH | 2026年10月1日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.34% | 75795 SH | 2026年8月19日 | 每日 |
| ESSC · Strategy Shares | 0.34% | 1785 NS | 2026年7月31日 | N-PORT |
| IWO · iShares Trust | 0.31% | 664357 SH | 2026年9月11日 | 每日 |
| FNY · First Trust Exchange-Traded Alpha... | 0.27% | 22505 NS | 2026年7月31日 | N-PORT |
| ROUS · Lattice Strategies Trust | 0.25% | 25676 NS | 2026年7月31日 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0.24% | 3125 NS | 2026年7月31日 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.20% | 477030 SH | 2026年8月19日 | 每日 |
| BBSC · J.P. Morgan Exchange-Traded Fund ... | 0.19% | 19797 NS | 2026年7月31日 | N-PORT |
| SMDX · Tidal Trust III | 0.19% | 3667 NS | 2026年7月31日 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0.19% | 1099640 SH | 2026年8月19日 | 每日 |
| IWM · iShares Trust | 0.18% | 2118779 SH | 2026年9月11日 | 每日 |
| RSSL · Global X Funds | 0.18% | 39691 NS | 2026年7月31日 | N-PORT |
| PWS · Pacer Funds Trust | 0.18% | 629 NS | 2026年7月31日 | N-PORT |
| ISCG · iShares Trust | 0.16% | 23005 SH | 2026年9月11日 | 每日 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.16% | 66833 SH | 2026年10月1日 | 每日 |
| LRGF · iShares Trust | 0.16% | 84774 SH | 2026年9月11日 | 每日 |
| VFMO · VANGUARD WELLINGTON FUND | 0.14% | 35428 SH | 2026年8月19日 | 每日 |
| FSMD · FIDELITY COVINGTON TRUST | 0.14% | 51459 NS | 2026年7月31日 | N-PORT |
| FHEQ · Fidelity Greenwood Street Trust | 0.14% | 18636 NS | 2026年7月31日 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Inde... | 0.13% | 5320 SH | 2026年10月1日 | 每日 |
| FBUF · Fidelity Greenwood Street Trust | 0.12% | 413 NS | 2026年7月31日 | N-PORT |
| FYEE · Fidelity Greenwood Street Trust | 0.11% | 3600 NS | 2026年7月31日 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.10% | 224327 NS | 2026年7月31日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.08% | 952071 SH | 2026年8月19日 | 每日 |
| VB · VANGUARD INDEX FUNDS | 0.08% | 1902509 SH | 2026年8月19日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.08% | 211842 SH | 2026年8月19日 | 每日 |
| FAD · First Trust Exchange-Traded Alpha... | 0.08% | 6756 NS | 2026年7月31日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.07% | 33487 NS | 2026年7月31日 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trus... | 0.06% | 18902 SH | 2026年10月1日 | 每日 |
| FNX · First Trust Exchange-Traded Alpha... | 0.06% | 12627 NS | 2026年7月31日 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.06% | 10557 SH | 2026年8月19日 | 每日 |
| ESML · iShares Trust | 0.06% | 22893 SH | 2026年9月11日 | 每日 |
| WSML · iShares Trust | 0.04% | 4360 SH | 2026年9月11日 | 每日 |
| TILT · FlexShares Trust | 0.01% | 4108 NS | 2026年7月31日 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.01% | 2636335 SH | 2026年8月19日 | 每日 |
| VT · VANGUARD INTERNATIONAL EQUITY IND... | 0.01% | 66405 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.01% | 6819 SH | 2026年8月19日 | 每日 |
| ESGV · VANGUARD WORLD FUND | 0.01% | 18275 SH | 2026年8月19日 | 每日 |
| ITOT · iShares Trust | 0.01% | 109219 SH | 2026年9月11日 | 每日 |
| IWV · iShares Trust | 0.01% | 22686 SH | 2026年9月10日 | 每日 |
| DFAC · Dimensional ETF Trust | 0.01% | 43296 NS | 2026年7月31日 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 1090 NS | 2026年7月31日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 284 NS | 2026年7月31日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 249 NS | 2026年7月31日 | N-PORT |
| IJR · iShares Trust | · | 5061986 SH | 2026年9月10日 | 每日 |
| IJT · iShares Trust | · | 784746 SH | 2026年9月9日 | 每日 |
| IWN · iShares Trust | · | 114658 SH | 2026年9月11日 | 每日 |
| XJR · iShares Trust | · | 11464 SH | 2026年8月31日 | 每日 |
| ISCB · iShares Trust | · | 3281 SH | 2026年9月11日 | 每日 |
| SMLF · iShares Trust | · | 64380 SH | 2026年9月11日 | 每日 |
PTCT 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 21 位分析师
买入
中位数目标
$101.00
+59.2%
6 28.6%
强烈买入
11 52.4%
买入
3 14.3%
持有
1 4.8%
卖出
0 0.0%
强烈卖出
12个月价格目标
14 位分析师 · 2026-10-01平均目标 $101.79 +60.4%
← 低于所有目标
当前价格 $63.46
最低$70.00
平均值$101.79
最高$137.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | · |
| SRRK | $4.78B | -13.4 | · | · | -157.9% | · |
| ORKA | $1.48B | -3.3 | · | · | -25.9% | · |
| COGT | $5.72B | -16.4 | · | · | -83.1% | · |
| MIRM | $4.10B | -168.1 | 54.7% | -4.5% | -8.2% | · |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | · |
| ERAS | $1.06B | -8.5 | · | · | -35.7% | · |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | · |
| RLAY | $1.47B | -5.3 | 53.4% | -1800.6% | -44.9% | · |
交易信号 近期买入/卖出信号，包含入场价和风险/回报比
目前没有公开信号 — 没有卡片被填写，这是诚实的。
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 七月 30, 2026 申报